Skip to main content
Premium Trial:

Request an Annual Quote

Jockeying for the Limelight Can Be a Contact Sport

Over at Bitesize Bio, Dan blogs about "emerging biomedical technologies" -- that is, the most-hyped angles in science. While the hype tends to be roughly proportional to the potential of the new tech, it doesn't change the fact that these tend to become scientific fads that attract a (perhaps undeservedly) high number of researchers. Beyond that, Dan writes, "Most scientists would agree that they try to ’sell’ their research to publishers and foundations by exaggerating the importance of findings or forthcoming studies, to advance their careers."

Hey, GTO didn't say it. But is it true?

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.